Victor Abler
Acadia Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Schizophrenia research and treatment, Botulinum Toxin and Related Neurological Disorders, Genetic Neurodegenerative Diseases
Most-Cited Works
- → Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials(2020)67 cited
- → Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study(2016)62 cited
- → Long‐term effects of rasagiline and the natural history of treated Parkinson's disease(2016)51 cited
- → Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis(2020)40 cited
- → Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis(2022)35 cited
- → Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting(2017)30 cited
- → Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States(2018)30 cited
- → Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States(2019)29 cited
- → Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson’s Disease (1991–2010)(2022)27 cited
- → An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression(2020)23 cited